Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Niraparib Efficacy in Patient With Unresectable Mesothelioma: A Randomised Phase II Trial of Niraparib Versus Active Symptom Control in Patients With Previously Treated Mesothelioma

NCT05455424 is registered in ClinicalTrials.gov with University Hospital Southampton NHS Foundation Trust as lead sponsor.

NCT NCT05455424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05455424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Niraparib Efficacy in Patient With Unresectable Mesothelioma: A Randomised Phase II Trial of Niraparib Versus Active Symptom Control in Patients With Previously Treated Mesothelioma
Lead sponsor
University Hospital Southampton NHS Foundation Trust
Phase
Phase 2
Overall status
Completed
Start date
July 11, 2022
Completion date
January 31, 2025
Enrollment
88 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

mesothelioma, malignant